Bladder EpiCheck® Included in 2022 European Association of Urology (EAU) Clinical Guidelines on Non-Muscle Invasive Bladder Cancer (NMIBC)

Clinical Guidelines Support Adoption of Urinary Biomarker Tests with High Sensitivity and Negative Predictive Values for High-Grade Disease to Replace and/or Postpone Cystoscopies in Low- and Intermediate-Risk NMIBC

Publication of Meta-Analysis in European Urology Oncology Showed Bladder EpiCheck has Best Performance Amongst Guideline-Recommended Urinary Biomarker Tests

Excerpt from the Press Release:

SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced its Bladder EpiCheck^® test has been included in the 2022 European Association of Urology (EAU) Clinical Guidelines for non-muscle invasive bladder cancer (NMIBC). The EAU guidelines aim to provide practical recommendations on the clinical management of NMIBC, to assist physicians in making informed treatment decisions with available scientific data.

The EAU guidelines state that urinary biomarker tests with high sensitivity and negative predictive values for high-grade disease, including a specific reference to Bladder EpiCheck, might be used to replace and/or postpone cystoscopies in low- and intermediate-risk NMIBC, and reduce the number of cystoscopies in this patient population.

Bladder cancer is the fifth most common cancer in the western world, but the costliest to care for, due to the need for prolonged surveillance. Because of high recurrence rate of the disease, patients undergo up to four follow-ups each year, which usually include cystoscopies that are invasive and painful.

“In follow up, many cystoscopies are negative, meaning the procedure was unnecessary. Apart from that, even when there is a high-grade recurrence, sensitivity of cystoscopies is certainly not 100%. The updated EAU guidelines illustrate that clinicians can improve NMIBC monitoring by replacing some of the cystoscopies with high-performing, non-invasive urinary markers,” said Professor Fred Witjes, Professor of Medical Sciences at Radboud University Medical Center and chair of the MIBC EAU guidelines. “In our hospital we have implemented such an alternating schedule with Bladder EpiCheck which benefits the patients and is cost effective.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release